These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 7694894)
41. Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients. Villa E; Buttafoco P; Merighi A; Grottola A; Ferretti I; Ferrari A; Callea F; Trande P; Rebecchi AM; Manenti F J Mol Med (Berl); 1995 May; 73(5):249-54. PubMed ID: 7545526 [TBL] [Abstract][Full Text] [Related]
42. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Shindo M; Di Bisceglie AM; Cheung L; Shih JW; Cristiano K; Feinstone SM; Hoofnagle JH Ann Intern Med; 1991 Nov; 115(9):700-4. PubMed ID: 1656828 [TBL] [Abstract][Full Text] [Related]
43. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298 [TBL] [Abstract][Full Text] [Related]
44. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Reichard O; Glaumann H; Frydén A; Norkrans G; Schvarcz R; Sönnerborg A; Yun ZB; Weiland O Hepatology; 1995 Apr; 21(4):918-22. PubMed ID: 7705800 [TBL] [Abstract][Full Text] [Related]
45. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. Laghi V; Toccaceli F; Rosati S; Monini A; Grimaldi M; Foglianti G; Canova N; Palazzini E Hepatogastroenterology; 1997; 44(16):1182-6. PubMed ID: 9261621 [TBL] [Abstract][Full Text] [Related]
46. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Shindo M; Hamada K; Koya S; Arai K; Sokawa Y; Okuno T Hepatology; 1996 Nov; 24(5):1018-23. PubMed ID: 8903369 [TBL] [Abstract][Full Text] [Related]
47. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. Misiani R; Bellavita P; Fenili D; Vicari O; Marchesi D; Sironi PL; Zilio P; Vernocchi A; Massazza M; Vendramin G N Engl J Med; 1994 Mar; 330(11):751-6. PubMed ID: 8107741 [TBL] [Abstract][Full Text] [Related]
48. Long-term follow-up study of serum IgM antibody to hepatitis C virus (HCV), HCV replication, and liver disease outcome in chronic hepatitis C. Quiroga JA; Herrero M; Castillo I; Navas S; Pardo M; Carreño V J Infect Dis; 1994 Sep; 170(3):669-73. PubMed ID: 7521377 [TBL] [Abstract][Full Text] [Related]
49. The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. Löhr HF; Gerken G; Roth M; Weyer S; Schlaak JF; Meyer zum Büschenfelde KH J Hepatol; 1998 Oct; 29(4):524-32. PubMed ID: 9824260 [TBL] [Abstract][Full Text] [Related]
50. [Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon]. Garrido A; Lepe JA; Guerrero FJ; Palomo S Enferm Infecc Microbiol Clin; 2000 Dec; 18(10):512-5. PubMed ID: 11198002 [TBL] [Abstract][Full Text] [Related]
51. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Shindo M; Ken A; Okuno T Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234 [TBL] [Abstract][Full Text] [Related]
52. [Changes in C100-3, and N14 antibodies in patients with chronic hepatitis C treated with interferon]. Sakurai K; Yagi K; Hanawa Y; Shibuya A; Shibata H; Uchiyama Y; Ohtani H Rinsho Byori; 1994 Feb; 42(2):171-5. PubMed ID: 7511184 [TBL] [Abstract][Full Text] [Related]
53. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Kobayashi Y; Watanabe S; Konishi M; Yokoi M; Kakehashi R; Kaito M; Kondo M; Hayashi Y; Jomori T; Suzuki S Hepatology; 1993 Dec; 18(6):1319-25. PubMed ID: 8244255 [TBL] [Abstract][Full Text] [Related]
54. Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to interferon-alpha. Löhr H; Nagel C; Dienes HP; Simpson B; Michel G; Goergen B; Meyer zum Büschenfelde KH; Gerken G Hepatology; 1994 Dec; 20(6):1383-9. PubMed ID: 7526999 [TBL] [Abstract][Full Text] [Related]
55. Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. Pozzato G; Moretti M; Crocé LS; Sasso F; Kaneko S; Unoura M; Kobayashi K; Crovatto M; Santini G; Tiribelli C J Med Virol; 1995 Apr; 45(4):445-50. PubMed ID: 7666045 [TBL] [Abstract][Full Text] [Related]
56. Anti-c100 antibodies to hepatitis C virus in patients with chronic hepatitis C virus infection treated with interferon. Nakano Y; Kiyosawa K; Sodeyama T; Tanaka E; Yoshizawa K; Furuta K; Nakatsuji Y; Urushihara A; Furuta S Scand J Gastroenterol; 1993 Apr; 28(4):335-42. PubMed ID: 8387696 [TBL] [Abstract][Full Text] [Related]
57. Antibodies to hepatitis C virus and hepatitis C virus infection. Yuki N; Hayashi N; Kasahara A; Hagiwara H; Fusamoto H; Kamada T Gastroenterol Jpn; 1993 May; 28 Suppl 5():76-9. PubMed ID: 7689512 [TBL] [Abstract][Full Text] [Related]
58. High dose interferon alpha-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response. Bellary S; Smith DG; Bankes P; Harris A; Shayiq R; Black M Am J Gastroenterol; 1995 Feb; 90(2):259-62. PubMed ID: 7847297 [TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of patients with chronic hepatitis C after interferon-alpha treatment. Teuber G; Dienes HP; Meyer zum Büschenfelde KH; Gerken G Digestion; 1996; 57(6):464-71. PubMed ID: 8913709 [TBL] [Abstract][Full Text] [Related]